FES PET/CT in Predicting Response in Patients With Newly Diagnosed Metastatic Breast Cancer Receiving Endocrine Therapy

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

99

Participants

Timeline

Start Date

May 4, 2016

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
HER2/Neu NegativeProgesterone Receptor NegativeProgesterone Receptor PositiveStage IV Breast Cancer AJCC v6 and v7
Interventions
PROCEDURE

Computed Tomography

Undergo PET/CT

DRUG

F-18 16 Alpha-Fluoroestradiol

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

PROCEDURE

Positron Emission Tomography

Undergo PET/CT

Trial Locations (25)

10029

Mount Sinai Hospital, New York

10065

Memorial Sloan Kettering Cancer Center, New York

19104

University of Pennsylvania/Abramson Cancer Center, Philadelphia

19111

Fox Chase Cancer Center, Philadelphia

19401

Fox Chase Cancer Center - East Norriton Hospital Outpatient Center, East Norriton

27599

UNC Lineberger Comprehensive Cancer Center, Chapel Hill

35233

University of Alabama at Birmingham Cancer Center, Birmingham

37232

Vanderbilt University/Ingram Cancer Center, Nashville

43210

Ohio State University Comprehensive Cancer Center, Columbus

46202

Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis

Sidney and Lois Eskenazi Hospital, Indianapolis

46290

Springmill Medical Center, Indianapolis

53066

ProHealth Oconomowoc Memorial Hospital, Oconomowoc

53149

ProHealth D N Greenwald Center, Mukwonago

53188

ProHealth Waukesha Memorial Hospital, Waukesha

UW Cancer Center at ProHealth Care, Waukesha

53792

University of Wisconsin Carbone Cancer Center - University Hospital, Madison

55905

Mayo Clinic in Rochester, Rochester

63110

Washington University School of Medicine, St Louis

75390

UT Southwestern/Simmons Cancer Center-Dallas, Dallas

84112

Huntsman Cancer Institute/University of Utah, Salt Lake City

90033

Los Angeles General Medical Center, Los Angeles

USC / Norris Comprehensive Cancer Center, Los Angeles

91010

City of Hope Comprehensive Cancer Center, Duarte

98195

University of Washington Medical Center - Montlake, Seattle

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT02398773 - FES PET/CT in Predicting Response in Patients With Newly Diagnosed Metastatic Breast Cancer Receiving Endocrine Therapy | Biotech Hunter | Biotech Hunter